Antithrombotic medication for stroke prevention

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 10, 2009, Pages 1245-1254

  Weimar, Christian ^a   Weber, Ralph ^a   Diener, Hans Christoph ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Anticoagulation; Antiplatelet; Ischemic stroke; Primary prevention; Secondary prevention; Transient ischemic attack

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; HEPARIN; LOTRAFIBAN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; SARPOGRELATE; TICLOPIDINE; TRIFLUSAL; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; BLEEDING; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEVICE THERAPY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG WITHDRAWAL; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; OPTIMAL DRUG DOSE; PATENT FORAMEN OVALE; PRIMARY PREVENTION; RECURRENT DISEASE; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; STROKE; TRANSIENT ISCHEMIC ATTACK;

ANTICOAGULANTS; BRAIN ISCHEMIA; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; STROKE;

EID: 70449982511     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.73     Document Type: Review

References (76)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic ana lysis of population health data. Lancet 367, 1747-1757 (2006).
2. Grau AJ, Weimar C, Buggle F et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke - The German Stroke Data Bank. Stroke 32, 2559-2566 (2001). (Pubitemid 33055306)
3. Appelros P, Stegmayr B, Terent A. Sex differences in stroke epidemiology: a systematic review. Stroke 40, 1082-1090 (2009).
4. Hankey GJ. Long-term outcome after ischaemic stroke/transient ischaemic attack. Cerebrovasc. Dis. 16 (Suppl. 1), 14-19 (2003).
5. Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic review and meta-ana lysis. Lancet Neurol. 6, 1063-1072 (2007).
6. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 62, 569-573 (2004).
7. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N. Engl. J. Med. 321, 129-135 (1989).
8. Peto R, Gray R, Collins R et al. Randomized trial of prophylactic daily aspirin in British male doctors. Brit. Med. J. 296, 313-316 (1988). (Pubitemid 18042841)
9. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study Report 14. JAMA 268, 1292-1300 (1992).
10. de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 357, 89-95 (2001).
11. Hansson L, Zanchetti A, Carruthers SG et al.; Hypertension Optimal Treatment (HOT) Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351, 1755-1762 (1998). (Pubitemid 28269185)
12. Iso H, Hennekens CH, Stampfer MJ et al. Prospective study of aspirin use and risk of stroke in women. Stroke 30, 1764-1771 (1999). (Pubitemid 29411812)
13. Bartolucci AA, Howard G. Meta-ana lysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am. J. Cardiol. 98, 746-750 (2006). (Pubitemid 44301007)
14. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-ana lysis of randomized controlled trials. JAMA 295, 306-313 (2006). •• In primary prevention, aspirin reduces the risk of stroke but not of myocardial infarction in women, while in men, only the risk of myocardial infarction but not stroke was significantly reduced.
15. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc. Dis. 25, 457-507 (2008). •• Current guidelines of the European Stroke Organzation on the management of acute stroke and secondary prevention.
16. Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354, 1706-1717 (2006).
17. Hart RG, Pearce LA, Aguilar MI. Meta-ana lysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146, 857-867 (2007).
18. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 8, 651-745 (2006). •• Current guidelines for the management of patients with atrial fibrillation.
19. Mant J, Hobbs FD, Fletcher K et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomized controlled trial. Lancet 370, 493-503 (2007).
20. Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet 367, 1903-1912 (2006).
21. Connolly SJ, Pogue J, Hart RG et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N. Engl. J. Med. 360, 2066-2078 (2009). • In patients with atrial fibrillation for whom vitamin K-antagonist therapy was unsuitable, the addition of clopidogrel to aspirin reduced the risk of major vascular events, especially stroke, but increased the risk of major hemorrhage.
22. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349, 1569-1581 (1997).
23. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 349, 1641-1649 (1997).
24. Hankey GJ, Berge E, Sandercock P. Anticoagulants versus antiplatelet agents for acute ischemic stroke. Stroke 34, 1571-1572 (2003). (Pubitemid 36693537)
25. Wong KS, Chen C, Ng PW et al. Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomized study. Lancet Neurol. 6, 407-413 (2007). (Pubitemid 46551851)
26. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomized controlled pilot trial. Lancet Neurol. 6, 961-969 (2007). (Pubitemid 47562312)
27. The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 31, 601-609 (2000).
28. Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized Phase 2 trial. Stroke 36, 880-890 (2005).
29. Adams HP Jr, Effron MB, Torner J et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 39, 87-99 (2008).
30. Antithrombotic Trialists' Collaboration. Collaborative meta-ana lysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71-86 (2002).
31. Algra A, van Gijn J. Cumulative metaana lysis of aspirin efficacy after cerebral ischaemia of arterial origin. J. Neurol. Neurosurg. Psychiatr. 66, 255 (1999). (Pubitemid 29103541)
32. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 353, 2373-2383 (2005).
33. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 297, 2018-2024 (2007). • Data in this systematic review do not support the routine, long-term use of aspirin dosages greater than 75-81 mg/day in the setting of cardiovascular disease prevention. Higher dosages, which may be commonly prescribed, do not better prevent events but are associated with increased risks of gastrointestinal bleeding.
34. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N. Engl. J. Med. 325, 1261-1266 (1991).
35. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results. J. Neurol. Neurosurg. Psychiatr. 54, 1044-1054 (1991).
36. Topol EJ, Easton D, Harrington RA et al. Randomized, double-blind, placebocontrolled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 108, 399-406 (2003).
37. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494-502 (2001). • Clopidogrel in addition to aspirin has beneficial effects in patients with acute coronary syndromes without ST-segment elevation. However, the risk of major bleeding is increased among patients treated with clopidogrel.
38. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomized controlled trial. Lancet Neurol. 6, 115-124 (2007). (Pubitemid 46097527)
39. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann. Neurol. 42, 857-865 (1997).
40. Mohr JP, Thompson JL, Lazar RM et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N. Engl. J. Med. 345, 1444-1451 (2001). • This double-blind secondary prevention trial did not show a significant benefit of warfarin over aspirin in patients with noncardioembolic stroke.
41. CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet 348, 1329-1339 (1996).
42. Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebocontrolled trial. Lancet 364, 331-337 (2004).
43. Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J. Am. Coll. Cardiol. 49, 1982-1988 (2007).
44. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143, 1-13 (1996). (Pubitemid 26402780)
45. Diener HC, Darius H, Bertrand-Hardy JM, Humphreys M. Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). Int. J. Clin. Pract. 55, 162-163 (2001). (Pubitemid 32390152)
46. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet 367, 1665-1673 (2006).
47. Halkes PH, Gray LJ, Bath PM et al. Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-ana lysis by risk. J. Neurol. Neurosurg. Psychiatr. 79, 1218-1223 (2008).
48. Sacco RL, Diener HC, Yusuf S et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N. Engl. J. Med. 359, 1238-1251 (2008). • The largest secondary prevention trial so far could not demonstrate any significant difference between aspirin and extendedrelease dipyridamole in the prevention of stroke or the composite cardiovascular end point.
49. Weimar C, Diener HC, Alberts MJ et al. The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the Reduction of Atherothrombosis for Continued Health (REACH) registry. Stroke 40, 350-354 (2009).
50. Weimar C, Goertler M, Rother J et al. Predictive value of the Essen stroke risk score and ankle brachial index in acute ischemic stroke patients from 85 German stroke units. J. Neurol. Neurosurg. Psychiatr. 79, 1339-1343 (2008). • External validation of a risk score for secondary prevention in stable cerebrovascular patients.
51. Costa J, Ferro JM, Matias-Guiu J, Alvarez-Sabin J, Torres F. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst. Rev. 3, CD004296 (2005).
52. Gent M, Blakely JA, Easton JD et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1, 1215-1220 (1989).
53. Steinhubl SR, Tan WA, Foody JM, Topol EJ; EPISTENT Investigators. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA 281, 806-810 (1999).
54. Gorelick PB, Richardson D, Kelly M et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 289, 2947-2957 (2003). (Pubitemid 37430096)
55. Huang Y, Cheng Y, Wu J et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomized, double-blind, pilot study. Lancet Neurol. 7, 494-499 (2008).
56. Shinohara Y, Nishimaru K, Sawada T et al. Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. Stroke 39, 1827-1833 (2008).
57. Chimowitz MI, Lynn MJ, Howlett-Smith H et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N. Engl. J. Med. 352, 1305-1316 (2005). • Only randomized trial in patients with intracranial stenosis, which was terminated prematurely due to an increased mortality with warfarin.
58. Kwon SU, Cho YJ, Koo JS et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebocontrolled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 36, 782-786 (2005).
59. Hagen PT, Scholz DG, Edwards WD. Incidence and size of ER-DP during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin. Proc. 59, 17-20 (1984).
60. Meissner I, Whisnant JP, Khandheria BK et al. Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Stroke Prevention: Assessment of Risk in a Community. Mayo Clin. Proc. 74, 862-869 (1999).
61. Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-ana lysis of case-control studies. Neurology 55, 1172-1179 (2000). (Pubitemid 30802997)
62. Mas JL, Arquizan C, Lamy C et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N. Engl. J. Med. 345, 1740-1746 (2001). (Pubitemid 34940229)
63. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 105, 2625-2631 (2002). (Pubitemid 34596039)
64. Slottow TL, Steinberg DH, Waksman R. Overview of the 2007 Food and Drug Administration circulatory system devices panel meeting on patent foramen ovale closure devices. Circulation 116, 677-682 (2007).
65. European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342, 1255-1262 (1993).
66. Flaker GC, Gruber M, Connolly SJ et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory ana lysis of Stroke Prevention using an Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF) trials. Am. Heart J. 152, 967-973 (2006). (Pubitemid 44637136)
67. Radziszewska B, Hart RG, Wolf PA, D'Agostino RB Sr, Cutler JA. Clinical research in primary stroke prevention: needs, opportunities, and challenges. Neuroepidemiology 25, 91-104 (2005). (Pubitemid 41022610)
68. Yusuf S, Pais P, Afzal R et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a Phase II, double-blind, randomized trial. Lancet 373, 1341-1351 (2009).
69. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke results from the national registry of atrial fibrillation. JAMA 285, 2864-2870 (2001). (Pubitemid 32537350)
70. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126, S234-S264 (2004).
71. Hart R, Benavente O, McBride R, Pearce L. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-ana lysis. Ann. Intern. Med. 131, 492-501 (1999). (Pubitemid 29482392)
72. Hart RG, Halperin JL, Pearce LA et al. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann. Intern. Med. 138, 831-838 (2003).
73. Leonardi-Bee J, Bath PM, Bousser MG et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-ana lysis of individual patient data from randomized controlled trials. Stroke 36, 162-168 (2005). (Pubitemid 40054197)
74. EARLY 3-months Aggrenox treatment started within 24 Hrs of ischemic stroke onset vs. after one week 100 mg ASA [NCT00562588] www.clinicaltrials.gov (Accessed 17 July 2009)
75. Trial of Cilostazol in Symptomatic intracranial Arterial Stenosis II (TOSS-2) [NCT00130039] www.clinicaltrials.gov (Accessed 17 July 2009)
76. Cilostazol-aspirin therapy against recurrent stroke with intracranial artery stenosis [NCT00333164] www.clinicaltrials.gov (Accessed 17 July 2009)